Open AccessImaging Early-Stage Metastases Using an 18F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant
Author(s) -
Christian Mason,
Lukas M. Carter,
Komal Mandleywala,
Paula Demétrio De Souza França,
JanPhilip Meyer,
Tanjeena Mamun,
Joseph M. Backer,
Marina V. Backer,
Thomas Reiner,
Jason S. Lewis
Publication year - 2020
Publication title -
molecular imaging and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.846
H-Index - 68
eISSN - 1860-2002
pISSN - 1536-1632
DOI - 10.1007/s11307-020-01555-z
Subject(s) - biodistribution , ex vivo , breast cancer , in vivo , positron emission tomography , metastasis , metastatic breast cancer , nuclear medicine , cancer research , preclinical imaging , cancer , chemistry , medicine , pathology , biology , microbiology and biotechnology
Metastatic breast cancer is the second leading cause of cancer-related death in women. The 5-year survival rate for metastatic breast cancer has remained near 26.9 % for over a decade. The recruitment of hematopoietic stem cells with high expression of the vascular endothelial growth factor receptor 1 (VEGFR-1) has been implicated in early stages of metastasis formation. We propose the use of an 18 F-labeled single-chain version of VEGF121, re-engineered to be selective for VEGFR-1 (scVR1), as a positron emission tomography (PET) imaging agent to non-invasively image early-stage metastases.